It is also important to consider a recent report that showed that doxorubicin increased HIF-1α expression in a tumour mouse model through a STAT1-nitric oxide dependent mechanism [31], which suggests that certain cancer cells may have a different response to doxorubicin in vivo. The gene discussed is STAT1; the disease is neoplasm.